PAM50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the ALTERNATE trial (Alliance A011106)
- Citation:
- Cancer Res vol 82 (4_supplement) abst PD9-03.
- Meeting Instance:
- SABCS 2021
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster/Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- 3910
- Pharmas:
- Genentech, AstraZeneca
- Grants:
- U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868, CPRIT RR140033, P50CA186784, P50-CA58223, U01CA214125, U24CA210954
- Corr. Author:
- Authors:
- Cynthia X. Ma Meenakshi Anurag Travis Dockter Jeremy Hoog Aranzazu Fernandez-Martinez Cheng Fan Richard Gibbs Souzan Sanati Kiran Vij Mark Watson Olwen Hahn Joseph Guenther Abigail Caudle Erika Crouch Amy Tiersten Monica Mita Wajeeha Razaq Tina J. Hieken Yang Wang A. Marilyn Leitch Gary W. Unzeitig Anna Weiss Eric P. Winer Kelly Hunt Ann H. Partridge Lisa A Carey Charles M. Perou Matthew J. Ellis Vera Suman
- Networks:
- CA016, KY015, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-OK003, LAPS-TX011, LAPS-TX035, NEWMEXICO, NY021, NY167, TX041, TX190
- Study
- Alliance-A011106
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: